Physician profile
Eric David Beachy
NPI 1881652188
$1,522.17
in general payments reported to CMS, 2019-2025
29 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $79.43 · 2021: $301 · 2022: $245 · 2023: $197 · 2024: $216 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $579.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $405.59 | 2019-2024 | Xarelto |
| Pfizer INC. | $226.60 | 2019-2021 | |
| Novo Nordisk INC | $129.96 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $129.56 | 2022-2025 | Vraylar |
| Astrazeneca Pharmaceuticals LP | $121.90 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $40.85 | 2022-2023 | M-M-R II, Gardasil 9, Vaxelis |
| Gilead Sciences, INC. | $33.34 | 2021-2023 | Epclusa |
| Amgen INC. | $33.29 | 2023-2024 | Repatha |
| Exact Sciences Corporation | $31.06 | 2025 | Cologuard Collection Kit |
| Boston Scientific Corporation | $30.30 | 2025 | Watchman Flx |
| Axsome Therapeutics, INC. | $29.60 | 2022 | |
| Glaxosmithkline, LLC. | $28.41 | 2019-2025 | Penmenvy, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $22.64 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.15 | 2025 | Koselugo |
| Lundbeck LLC | $22.10 | 2025 | Rexulti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19.22 | 2024 | Voquezna |
| Lilly USA, LLC | $19.06 | 2023 | Zepbound |
| Amarin Pharma, INC. | $17.88 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $17.30 | 2023 | Inpefa |
| Insulet Corporation | $17.00 | 2023 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $16.55 | 2023 | |
| Grifols USA, LLC | $16.15 | 2020 | |
| Alkermes, INC. | $15.83 | 2025 | Lybalvi |
| Global Blood Therapeutics, INC. | $15.69 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.50 | 2025 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $12.91 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.63 | 2021 | |
| Sanofi-Aventis U.S. LLC | $11.07 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Beachy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.